Stock OCUL OCULAR THERAPEUTIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Real-time Estimate Cboe BZX
Other stock markets
 11:16:53 2024-04-29 am EDT 		5-day change 1st Jan Change
4.965 USD +4.64% Intraday chart for Ocular Therapeutix, Inc. -0.99% +12.67%
Apr. 18 Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup DJ
Apr. 18 Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy
AQ
Ocular Therapeutix : Amendment No. 3 to 2019 Inducement Stock Incentive Plan - Form 8-K
PU
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
AQ
Ocular Therapeutix Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
AQ
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
AQ
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
AQ
Ocular Therapeutix Reports Inducement Grants under Nasdaq Listing Rule 5635(4) to Senior Vice President of Global Head of Biometrics
AQ
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
AQ
Ocular Therapeutix Announces Positive Phase 2 PAXTRAVA Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
AQ
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
AQ
Ocular Therapeutix to Present Data at the 2024 ASCRS Annual Meeting
AQ
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
AQ
Ocular Therapeutix: Q4 Earnings Snapshot
AQ
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
AQ
Ocular Therapeutix to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
AQ
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
AQ
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
AQ
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
AQ
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
AQ
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority for DEXTENZA for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCUL Stock
  4. News Ocular Therapeutix, Inc.
  5. Press Releases